Nautilus Biotechnology Files 8-K on Shareholder Vote Matters

Ticker: NAUT · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1808805

Nautilus Biotechnology, INC. 8-K Filing Summary
FieldDetail
CompanyNautilus Biotechnology, INC. (NAUT)
Form Type8-K
Filed DateJun 13, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, filing-update

Related Tickers: ARYA

TL;DR

NAUT filed an 8-K for shareholder vote items - watch for updates on what they're voting on.

AI Summary

Nautilus Biotechnology, Inc. filed an 8-K on June 13, 2024, to report on matters submitted to a vote of its security holders. The filing indicates a change in the company's status or corporate actions requiring shareholder approval, though specific details of the vote are not elaborated in this excerpt.

Why It Matters

This filing signals that Nautilus Biotechnology, Inc. has taken actions requiring shareholder consent, which could impact the company's future direction or governance.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can indicate significant corporate events or changes that may affect the company's stock price and future operations.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Nautilus Biotechnology, Inc.'s security holders on June 13, 2024?

The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in this excerpt of the 8-K.

What was Nautilus Biotechnology, Inc.'s former name?

Nautilus Biotechnology, Inc.'s former name was ARYA Sciences Acquisition Corp III.

When did the company change its name from ARYA Sciences Acquisition Corp III?

The date of the name change was April 8, 2020 (20200408).

Where are Nautilus Biotechnology, Inc.'s principal executive offices located?

The principal executive offices are located at 2701 Eastlake Avenue East, Seattle, Washington, 98102.

What is the SEC file number for Nautilus Biotechnology, Inc.?

The SEC file number for Nautilus Biotechnology, Inc. is 001-39434.

Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-06-13 16:25:56

Key Financial Figures

Filing Documents

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. Nautilus Biotechnology, Inc. (the "Company") held its 2024 annual meeting of stockholders on June 13, 2024 (the "Annual Meeting"). Of the 125,265,015 shares of the Company's common stock outstanding as of the record date of April 16, 2024, 105,300,784 shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below: 1. Election of Class III Directors. The following nominees were elected to serve as Class III directors, each to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Melissa Epperly 92,055,005 674,206 12,571,573 Matthew L. Posard 90,642,659 2,086,552 12,571,573 Karen Akinsanya 89,933,948 2,795,263 12,571,573 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting: Votes For Votes Against Abstentions 105,058,709 172,887 69,188

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 13, 2024 NAUTILUS BIOTECHNOLOGY, INC. By: /s/ Sujal Patel Name: Sujal Patel Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing